References

Grow Taller 4 Idiots

How to Grow Taller

Get Instant Access

1. Griffin JE, Wilson JD. Disorders of the testes and the male reproductive tract. In: Wilsom JD, Foster DW, Kronenberg HM, Larsen PD eds. Williams Textbook of Endocrinology, 9th ed. WB Saunders Company, Philadelphia, 1998, pp. 819-875.

2. Lin T, Clark R. Disorders of male reproductive function. In: Moore WT, Eastman RC, eds. Diagnostic Endocrinology, 2nd ed., St. Louis: Mosby, 1996, pp. 339-371.

3. Shimon I, Melmed S. Management of pituitary tumors. Ann Intern Med 1998;129:472-483.

4. Cheung CY. Prolactin suppresses luteinizing hormone secretion and pituitary responsiveness to luteinizing hormone-releasing hormone by a direct action at the anterior pituitary. Endocrinology 1983;113:632-638.

5. Bouchard P, Lagoguey M, Brailly S, Schaison G. Gonadotropin-releasing hormone pulsatile administration restores luteinizing hormone pulsatility and normal testosterone levels in males with hyperpro-lactinemia. J Clin Endocrinol Metab 1985;60:258-262.

6. Hondo E, Kurohmaru M, Sakai S, Ogawa K, Hayashi Y. Prolactin receptor expression in rat spermato-genic cells. Biol Reprod 1995;52:1284-1290.

7. Winters SJ. Diurnal rhythm of testosterone and luteinizing hormone in hypogonadal men. J Androl 1991;12:185-190.

8. Manandhar MS, Thomas JA. Effect of prolactin on the metabolism of androgens by the rat ventral prostate gland in vitro. Invest Urol 1976;14:20-22.

9. Waeber C, Reymond O, Reymond M, Lemarchand-Beraud T. Effects of hyper- and hypoprolactinemia on gonadotropin secretion, rat testicular luteinizing hormone/human chorionic gonadotropin receptors and testosterone production by isolated Leydig cells. Biol Reprod 1983;28:167-177.

10. Franks S, Jacobs HS, Martin N, Nabarro JD. Hyperprolactinemia and impotence. Clin Endocrinol 1978;8:277-287.

11. Magrini B, Ebiner JR, Burckhardt P, Felber JP. Study on the relationship between plasma prolactin and androgen metabolism in man. J Clin Endocrinol Metab 1976;43:944-947.

12. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 2000;85:3053-3057.

13. Kelly PA, Binart N, Lucas B, Bouchard B, Goffin V. Implications of multiple phenotypes observed in prolactin receptor knockout mice. Front Neuroendocrinol 2001;22:140-145.

14. Shimon I, Melmed S. Diagnosis and treatment of pituitary disease. Psycother Psychosom 1998;67:119-124.

15. Conner P, Fried G. Hyperprolactinemia: etiology, diagnosis and treatment alternatives. Acta Obstet Gynecol Scand 1998;77:249-262.

16. Biller BMK, Luciano A. Guideliness for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999;44(suppl):1075-1084.

17. Winters SJ, Troen P. Altered pulsatile secretion of luteinizing hormone in hyponadal men with hyperprolactinemia. Clin Endocrinol 1984;21:257-263.

18. Anderson JR, Antoun N, Burnet N, et al. Neurology of the pituitary gland. J Neurol Neurosurg Psychiatry 1999;66:703-721.

19. FitzPatrick M, Tarataglino L, Hollander MD, Zimmerman RA, Flanders AE. Imaging of sellar and parasellar pathology. Radiol Clin North Am 1999;37:101-121.

20. Naidich MJ, Russel EJ. Current approach to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am 1999;28:45-79.

21. Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 2002;11:787-800.

22. Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet 1998;352:1455-1461.

23. Colao A, De Rosa M, Sarnacchiaro F, et al. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol 1996;135:548-552.

24. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-2522.

25. Ferrari CI, Abs R, Bevan JS, et al. Treatment of macroprolactinomas with cabergoline: a study of 85 patients. Clin Endocrinol 1997;46:409-412.

26. Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 1999;22:354-359.

27. De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998;138:286-293.

28. Colao A, Annunziato L, Lombardi G. Treatment of prolactinomas. Ann Med 1998;30:452-459.

29. Colao A, Di Sarno AM, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876-883.

30. Molitch ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999;28:143-169.

31. Tominaga A, Uozumi T, Arita K, et al. Effects of surgery on testosterone secretion in male patients with pituitary adenomas. Endocr J 1996;43:307-312.

32. Isurugi K, Kajiwara T, Hosaka Y, Minowada S. Successful gonadotrophin treatment of hypogonadism in postoperative patients with macroprolactinoma and persistent hyperprolactinaemia. Int J Androl 1993;16:306-310.

33. Wass JA, Sheppard MC. New treatments for acromegaly. J Royal Coll Physic London 1998;32:113-117.

34. Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 1992;21:877-901.

35. Katznelson L, Kleinberg D, Vance ML, et al. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol 2001;54:183-188.

36. Bartlett JMS, Charlton HM, Robinson IC, Nieschlag E. Pubertal development and testicular function in the male GH-deficient rat. J Endocrinol 1990;126:193-201.

37. Spiteri-Grech J, Barlett JMS, Nieschlag E. Regulation of testicular insulin-like growth factor-I in pubertal growth hormone-deficient male rats. J Endocrinol 1991;131:279-285.

38. Sjogren I, Joussou M, Madej A, Johansson HE, Ploen L. Effects of very high doses of human growth hormone (hGH) on the male reproductive system in the dog. Andrologia 1998;30:37-42.

39. Roellsema F, Moblenaar AJ, Frolich M. The influence of bromocriptine and transsphenoidal surgery on urinary androgen metabolic excretion in acromegaly. Acta Endocrinol 1984;107:302-311.

40. Zweirska-Korczala K, Ostrowska Z, Zych F, Buntner B. The levels of pituitary-testicular axis hormones and SHBG in active acromegaly following bromocriptine treatment. Endocr Regul 1991;25:211-216.

41. Schwander J, Hauri C, Zapf J, Froesch E. Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver; dependence on growth hormone status. Endocrinology 1983;113:297-305.

42. Lindstedt G, Lindberg P, Hammond G, Vihko R. Sex hormone binding globulin-still many questions. Scand J Clin Lab Invest 1985;45:1-6.

43. Kleinberg DL, Todd J. Evidence that human growth hormone is a potent lactogen in primates. J Clin Endocrinol Metab 1980;51:1009-1013.

44. Colao A, Marzullo P, Spiezia S, et al. Effect of growth hormone (GH) and insulin-like growth factor-1 on prostate disease: an ultrasonographic and endocrine study in acromegaly, GH deficiency and healthy subjects. J Clin Endocrinol Metab 1999;84:1986-1991.

45. Colao A, Marzullo P, Ferone D, et al. Prostate hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 1998;83:775-779.

46. Duncan E, Wass AH. Investigation protocol: acromegaly and its investigation. Clin Endocrinol 1999;50:285-293.

47. Veznedaroglu E, Armonda RA, Andrews DW. Diagnosis and therapy for pituitary tumors. Curr Opin Oncol 1999;11:27-31.

48. Newman CB. Medical therapy for acromegaly. Endocrinol Metab Clin North Am 1999;28:171-190.

49. Ben-Shlomo A, Melmed A. Acromegaly. Endocrinol Metab Clin North Am 2001;30:565-583.

50. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82:18-22.

51. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients—a clinical research center study. J Clin Endocrinol Metab 1995;80:2768-2775.

52. Flogstad AK, Halse J, Bakke S, Lancranjan I, Bruns C, Jervell J. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab 1997;82:23-28.

53. Colao A, De Rosa M, Pivonello R, et al. Short-term suppression of GH and IGF-1 levels improves gonadal function and sperm parameters in men with acromegaly. J Clin Endocrinol Metab 2002;87:4193-4197.

54. Colao A, Ferone D, Marzullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997;82:518-523.

55. Van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-1759.

56. Trainer P, Drake W, Katznelson L, et al. Treatment of acromegaly with growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-1177.

57. Herman-Bonert VS, Zib K, Scarlett JA, Melmed S. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 2000;85:2958-2961.

58. Luton JP, Thieblot P, Valcke JC, Mahoudeau JA, Bricaire H. Reversible gonadotropin deficiency in male Cushing's disease. J Clin Endocrinol Metab 1977;45:488-495.

59. Chandran UR, Attardi B, Friedman R, Zheng ZW, Roberts JL, Defranco DB. Glucocorticoid repression of the mouse gonadotropin-releasing hormone gene is mediated by promoter elements that are recognized by heteromeric complexes containing glucocorticoid receptor. J Biol Chem 1996;271:20412-20420.

60. Gao HB, Tong MH, Hu YQ, Guo QS, Ge R, Hardy MP. Glucocorticoid induces apoptosis in rat Leydig cells. Endocrinology 2002;143:130-138.

61. Sankar BR, Maran RR, Sudha S, Govindarajulu P, Balasubramanian K. Chronic corticosterone treatment impairs Leydig cell 11ß-hydroxysteroid dehydrogenase activity and LH-stimulated testosterone production. Horm Metab Res 2000;32:142-146.

62. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations. Bull Johns Hopkins Hosp 1932;137:50-54.

63. Katz J, Bouloux PMG. Cushing's: how to make the diagnosis. Practitioner 1999;243:118-123.

64. Contreras LN, Hane S, Tyrrell JB. Urinary cortisol in the assessment of pituitary-adrenal function: utility of 24-hour and spot determination. J Clin Endocrinol Metab 1986;62:965-969.

65. Findling JW, Raff H. Newer diagnostic techniques and problems in Cushing's disease. Endocrinol Metab Clin North Am 1999;28:191-210.

66. Findling JW. Diagnosis and differential diagnosis of Cushing's syndrome. Meet The Professor—Endo 2002. San Francisco, June 19-22, 2002, pp. 87-94.

67. Invitti C, Pecori Giraldi F, De Martin M, Cavagnini F, The Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal axis. Diagnosis and management of Cushing's syndrome results of an Italian multicentre study. J Clin Endocrinol Metab 1999;84:440-448.

68. Tsigos C, Kamilaris TC, Chrousos GP. Adrenal disease. In: Moore WT, Eastman RC, eds. Diagnostic Endocrinology, 2nd ed., St. Louis: Mosby, 1996, pp. 125-156.

69. Colao A, Faggiano A, Pivonello R, Giraldi FP, Cavagnini F, Lombardi G. Study Group of the Italian Endocrinology Society on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. Eur J Endocrinol 2001;144:499-507.

70. Colao A, Merola B, Tripodi FS, et al. Simultaneous and bilateral inferior petrosal sinus sampling for the diagnosis of Cushing's syndrome: comparison of multihormonal assay, baseline multiple sampling and ACTH-releasing hormone test. Horm Res 1993;40:209-216.

71. Zarrilli L, Colao A, Merola B, et al. Corticotropin-releasing hormone test: improvement of the diagnostic accuracy of simultaneous and bilateral inferior petrosal sinus sampling in patients with Cushing syndrome. World J Surg 1995;19:150-153.

72. McKenna TJ, Lorber D, Lacroix A, Rabin D. Testicular activity in Cushing's disease. Acta Endocrinol (Copenh) 1979;91:501-510.

73. Smals AG, Kloppenborg PW, Benraad TJ. Plasma testosterone profiles in Cushing's syndrome. J Clin Endocrinol Metab 1977;45:240-245.

74. Mason RB, Nieman LK, Doppman JL, Oldfield EH. Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function. J Neurosurg 1997;87:343-351.

75. Sonino N, Boscaro M. Medical therapy for Cushing's disease. Endocrinol Metab Clin North Am 1999;28:211-222.

76. Colao A, Lombardi G, Annunziato L. Cabergoline. Expert Opin Pharmacother 2000;1:555-574.

77. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson's syndrome after 1 year treatment with cabergoline. J Endocrinol Invest 1999;22:860-865.

78. Klibanski A. Nonsecreting pituitary tumors. Endocrinol Metab Clin North Am 1987;16:793-804.

79. Katznelson L, Alexander JM, Klibanski A. Clinical review 45. Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1993;76:1089-1094.

80. Snyder PJ. Clinically nonfunctioning pituitary adenomas. Endocrinol Metab Clin North Am 1993;22:163-175.

81. Arafah BM. Reversible hypopituarism in patients with large nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1986;62:1173-1179.

82. Arafah BM, Kailani SH, Nekl KE, Gold RS, Selman WR. Immediate recovery of pituitary function after transphenoidal resection of pituitary macroadenomas. J Clin Endocrinol Metab 1994;79:348-354.

83. Ebersold MJ, Quast LM, Laws ERjr, Scheithauer B, Randall RV. Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas. J Neurosurg 1986;334:246-254.

84. Nobels FRE, de Herder WW, van den Brink WM, et al. Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma. Eur J Endocrinol 2000;143:615-621.

85. Colao A, Ferone D, Lastoria S, et al. Hormone levels and tumor size response to quinagolide and caber-goline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clin Endocrinol 2000;52:437-445.

86. Lamberts SWJ, de Herder WW, van der Lely AJ. Pituitary insufficiency. Lancet 1998;352:127-134.

87. Freda PU, Post KD. Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am 1999;28:81-117.

88. Shin JL, Asa SL, Woodhouse LJ, Smyth HS, Ezzat S. Cystic lesions of the pituitary: clinicopathologi-cal features distinguishing craniopharyngioma, Rathke's cleft cyst, and arachnoid cyst. J Clin Endocrinol Metab 1999;84:3972-3982.

89. Molitch ME. Sellar masses. Meet the Professor—Endo 2002. San Francisco, June 19-22, 2002, pp. 272-277.

90. Thorner MO, Lee Vance M, Laws ER, Howath E, Kovacs K. The anterior pituitary. In: Wilsom JD, Foster DW, Kronenberg HM, Larsen PD, eds. Williams Textbook of Endocrinology, 9th ed. WB Saun-ders Company, Philadelphia, 1998, pp. 249-340.

91. Bloom DL. Mucocle of the maxillary and sphenoidal sinuses. Radiology 1965;85:1103-1110.

92. Herzog KM, Tubbs RR. Langherans cell histiocytosis. Adv Anat Pathol 1998;5:347-358.

93. Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993;328:87-94.

94. Lee SC, Zasler ND, Kreutzer JS. Male pituitary-gonadal dysfunction following severe traumatic brain injury. Brain Inj 1994;8:571-577.

95. Benvenga S, Campenni A, Ruggeri RM, Trimarchi F. Hypopituarism secondary to head trauma. J Clin Endocrinol Metab 2000;85:1353-1361.

96. Valenta LJ, De Feo DR. Post-traumatic hypopituarism due to a hypothalamic lesion. Am J Med 1980;68:614-617.

Was this article helpful?

0 0
Supplements For Diabetics

Supplements For Diabetics

All you need is a proper diet of fresh fruits and vegetables and get plenty of exercise and you'll be fine. Ever heard those words from your doctor? If that's all heshe recommends then you're missing out an important ingredient for health that he's not telling you. Fact is that you can adhere to the strictest diet, watch everything you eat and get the exercise of amarathon runner and still come down with diabetic complications. Diet, exercise and standard drug treatments simply aren't enough to help keep your diabetes under control.

Get My Free Ebook


Post a comment